Why TRT Raised Your Blood Pressure (and How to Fix It)
Your cardiovascular system is built around a set of assumptions about how much blood it needs to move, and testosterone changes those assumptions in three separate ways at the same time.
That is the frame you need before anything else makes sense. TRT does not raise blood pressure through one mechanism. It raises it through three, and each one has a different cause, a different lab marker to track, and a different fix. When people say testosterone is bad for blood pressure, they are usually reacting to unmanaged versions of all three happening at once.
Start with the full chain, then we can go deeper into each one.
Testosterone signals the kidneys and bone marrow to produce more red blood cells through something called erythropoiesis, which is just the process your body uses to manufacture red blood cells. More red blood cells means thicker blood, and thicker blood creates more resistance inside your vessels, and more resistance means your heart has to push harder to move the same volume, and that pushing harder is what shows up as elevated blood pressure. Separately, testosterone increases total blood volume by causing the kidneys to retain more fluid, which adds more load to the cardiovascular system even if your blood is not thicker. And on top of that, testosterone gets converted into estradiol through a process called aromatization, and if estradiol goes too high it causes additional water retention on its own.
Three different pathways. Three different levers to manage.
The hematocrit story is the most documented of the three. A randomized controlled trial published in 2024 in the Journal of Hypertension tracked men whose hematocrit rose more than 6% on testosterone therapy. That group saw their systolic blood pressure increase by 13.2 mmHg compared to placebo. That is not a marginal change. That is the difference between normal blood pressure and a reading that would concern most doctors.
The reason the relationship is so direct is that hematocrit and blood pressure are physically linked. Blood viscosity, which is how thick or resistant the blood is to flow, rises with hematocrit, and the relationship is not linear the way you might hope. As hematocrit climbs past the mid-50s, small increases in red blood cell concentration produce larger and larger jumps in resistance. The heart does not get a warning. It just starts working harder to move the same volume through narrower, thicker channels.
Testosterone drives this in a dose-dependent way. Research from 2008 in the Journal of Clinical Endocrinology and Metabolism showed that hemoglobin and hematocrit rise in a linear fashion as testosterone dose increases. Higher dose, more red blood cell production, higher hematocrit, more vascular resistance. The dose-response relationship is clean and consistent.
The clinical threshold that most protocols use is 54%. Once hematocrit crosses that number, the standard guidance from a 2023 review in European Urology Focus is to reduce the dose or, in some cases, pause therapy until it comes back down. Therapeutic phlebotomy, which is simply donating blood or having blood drawn to reduce red blood cell volume, is also used but does not address the root cause if the dose remains unchanged.
Now move to the estradiol piece, because this one trips up a lot of clinics.
When testosterone converts to estradiol through aromatization, that estradiol causes the kidneys to retain sodium and water. More extracellular water means more blood volume. More blood volume means more pressure against the vessel walls. A study from 2005 in the Journal of Clinical Endocrinology and Metabolism confirmed that testosterone independently increases extracellular water through effects on the renal tubules, which are the filtering structures inside the kidney. So water retention is partly a direct testosterone effect and partly an estradiol effect layered on top.
The instinct in a lot of clinics is to crush estradiol with an aromatase inhibitor the moment a patient reports water retention or blood pressure creep. That instinct causes its own problem.
Estradiol is cardiovascular protective. It maintains vessel elasticity, supports healthy endothelial function, and has vasodilatory effects, meaning it helps vessels relax and widen rather than staying constricted. Research in animal models, including a 2022 study in the American Journal of Physiology, showed that blocking aromatase to suppress estradiol actually increased mean arterial pressure. When you eliminate estradiol trying to fix water retention, you lose the cardiovascular protection at the same time, and the net effect on blood pressure can be neutral or even negative.
The target range for estradiol on TRT is roughly 20 to 40 picograms per milliliter on a sensitive assay. Below that range, you lose the protective effects. Above that range, the fluid retention becomes problematic. The better way to land in that window is through injection frequency rather than aromatase inhibitor use. More frequent, smaller injections produce smaller peaks in testosterone and therefore smaller spikes in aromatization, which keeps estradiol more stable over time without suppressing it artificially.
The third mechanism is the one no lab panel will catch, and that is blood volume expansion against a cardiovascular system that is not conditioned to handle it.
Testosterone increases total blood volume. That is not a side effect. It is a physiological response. A conditioned cardiovascular system, meaning a heart and a network of vessels that have been trained through aerobic exercise, adapts to that expanded volume by becoming more efficient. The heart becomes a better pump. The vessels become more elastic. Resting blood pressure can actually decrease as a result. An unconditioned system does not have that adaptive capacity, so the expanded volume just means more pressure.
This is why cardio is not optional on TRT. It is the mechanism by which the cardiovascular system learns to handle what testosterone is doing to blood volume.
When all three of those variables are managed correctly, the long-term blood pressure story on TRT looks very different from what most people expect. A study of 737 men on long-term testosterone therapy, published in World Journal of Men's Health in 2024, found that men who were not on blood pressure medication saw their systolic blood pressure drop by about 12.5 points over time. In the same study, 33 out of 202 men who started on antihypertensive medication were eventually able to discontinue it.
The mechanism behind that outcome is the same system working in the other direction. Well-managed TRT improves body composition, reduces metabolic dysfunction, supports cardiovascular conditioning, and keeps estradiol in a protective range. All of those things put downward pressure on blood pressure over time.
The practical protocol is simple. Get a hematocrit check every six months and bring your provider in if it climbs above 54. Get a sensitive estradiol test and use injection frequency to stay in the 20 to 40 range. Make aerobic exercise a consistent part of the protocol, not an afterthought.
Testosterone does not raise blood pressure. Testosterone raises blood pressure when the three systems it affects are left unmanaged. The difference between those two statements is the difference between a therapy that works and one that creates problems you then have to treat separately.
References
- Olesen TB, Glintborg D, Johnk F, et al. 2024. Blood pressure responses to testosterone therapy are amplified by hematocrit levels in opioid-induced androgen deficiency. Journal of Hypertension, 423, 531-540. Finding: Office SBP increased 6.2 mmHg in testosterone group vs 7.0 mmHg decrease in placebo net 13.2 mmHg. Men with hematocrit rise >6% saw clinically relevant BP increases. Source
- Coviello AD, Kaplan B, Lakshman KM, et al. 2008. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology and Metabolism, 933, 914-919. Finding: Hemoglobin and hematocrit increased in a linear, dose-dependent fashion. Source
- Almutlaq RN, Newell-Fugate AE, Evans LC, et al. 2022. Aromatase inhibition increases blood pressure and markers of renal injury in female rats. American Journal of Physiology Renal Physiology, 3232, F170-F181. Finding: Blocking aromatase increased mean arterial pressure. Source
- Hackett G, Mann A, Haider A, et al. 2024. Testosterone replacement therapy: effects on blood pressure in hypogonadal men. World Journal of Mens Health, 422, 431-443. Finding: Long-term TRT associated with significant SBP and DBP reductions. 33 of 202 men on antihypertensives discontinued them. Source
- Agrawal P, Singh SM, Kohn T. 2023. Management of erythrocytosis in men receiving testosterone therapy. European Urology Focus, 91, 139-142. Finding: Hematocrit >54% requires dose decrease or discontinuation. Source
- Johannsson G, Gibney J, Wolthers T, et al. 2005. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. Journal of Clinical Endocrinology and Metabolism, 907, 3891-3896. Finding: Testosterone independently increased extracellular water through renal tubule effects. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.